Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BRCA
Pharma
NICE reverses its call on Talzenna after Pfizer discount
With a price discount from Pfizer, England's NICE has given breast cancer treatment Talzenna a thumbs up after rejecting it six months ago.
Kevin Dunleavy
Jan 19, 2024 7:47am
FDA signs off on J&J's prostate cancer combo therapy Akeega
Aug 14, 2023 11:52am
AZ, Merck's Lynparza wins new use in prostate cancer subgroup
Jun 1, 2023 11:40am
Tesaro undercuts PARP rivals with Zejula's $118K price tag
Apr 20, 2017 10:30am
